Sex Hormone-Binding Globulin as a marker for the thrombotic risk of hormonal contraceptives: reply to a rebuttal

Raps, M.; Helmerhorst, F.M.; Fleischer, K.; Hylckama, V.A. van; Stegeman, B.H.; Thomassen, S.; ... ; Vliet, H.A.A.M. van (2012)

Other

Kluft et al. question the design of our recent study regarding Sex Hormone-Binding Globulin (SHBG) as marker for the risk of venous thrombosis during use of hormonal contraceptives (1). They state that when measured only in women 'on-treatment', SHBG showed a very weak association with normalized activated protein C sensitivity ratios (nAPCsr) determined with the thrombin generation-based APC resistance test. Hence, in their opinion SHBG is not a surrogate marker for venous thrombosis. They claim this statement is supported by a recent publication of Stegeman et al. (2). © 2012 International Society on Thrombosis and Haemostasis.

• All authors: Raps, M.; Helmerhorst, F.M.; Fleischer, K.; Hylckama, V.A. van; Stegeman, B.H.; Thomassen, S.; Rosendaal, F.R.; Rosing, J.; Ballieux, B.E.P.B.; Vliet, H.A.A.M. van
• Date: 2012-11-24
• Title of host publication: Journal of Thrombosis and Haemostasis
• DOI: doi:10.1111/jth.12080